$Savara (SVRA.US)$ Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024
2 MINUTES AGO, 8:05 AM EST
VIA BUSINESSWIRE
Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from...

$bioAffinity Technologies (BIAF.US)$
WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement

$Fusion Fuel Green (HTOO.US)$ Have a peek🤫

$Savara (SVRA.US)$ Reuters· 
Savara to Present New Data From Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2024 September 7th thru 11th

$Genius Group (GNS.US)$ 6$

$Imunon (IMNN.US)$ 30$ today

$bioAffinity Technologies (BIAF.US)$ news

$SOBR Safe (SOBR.US)$ get ready

$AMTD Digital (HKD.US)$ 2k again?

$SOBR Safe (SOBR.US)$ I know something you don't know 🤣🤣👋👋👋